Metagenomi Therapeutics (MGX) Market Capitalization (2024 - 2026)

Metagenomi Therapeutics (MGX) has reported Market Capitalization for 3 consecutive years, with $45.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Market Capitalization fell 19.07% year-over-year to $45.0 million in Q2 2026; TTM through Jun 2026 was $45.0 million, a 19.07% decrease from a year earlier, with the FY2025 full-year figure at $60.9 million, down 54.88% from the prior year.
• Market Capitalization was $45.0 million for Q2 2026 at Metagenomi Therapeutics, down from $50.4 million in the prior quarter.
• Over five years, Market Capitalization peaked at $223.0 million in Q1 2024 and troughed at $45.0 million in Q2 2026.
• A 3-year average of $94.4 million and a median of $71.1 million in 2024 frame the typical range for Market Capitalization.
• The widest YoY moves for Market Capitalization: up 9.55% in 2025, down 77.2% in 2025.
• Over 3 years, Market Capitalization stood at $135.1 million in 2024, then sank by 54.88% to $60.9 million in 2025, then fell by 26.24% to $45.0 million in 2026.
• The last three Market Capitalization figures came in at $45.0 million (Q2 2026), $50.4 million (Q1 2026), and $60.9 million (Q4 2025), per Business Quant data.